ARTD9 counteracts the IFNγ-dependent anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis and induces an oncogenic switch in high-risk HR-DLBCL that transforms STAT1 from a tumor suppressor to a proto-oncogene[23]. Here, PARP9 is linked to neoplasm.